The dry powder inhalation composition comprising (1) salmeterol xinafoate having mean particle size in range of 2.0μ-6μ microns and a tapped density in the range of 0.20 g.cm-3to 0.45 g.cm-3and (2) optionally, one or more other active ingredients and pharmaceutically acceptable carrier.一種乾粉吸入組成物,包括:(1)沙美特羅羥萘甲酸鹽,具有範圍在2.0μ-6μ微米的平均粒子大小及範圍在0.20 g.cm-3至0.45 g.cm-3的壓實密度;及(2)可選地,一或更多其他活性成分及醫藥可接受載體。